Compare NICE Ltd (NICE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Sana Biotechnology Inc — how do they compare? NICE Ltd trades at $117.97 (market cap $6.81B), while Sana Biotechnology Inc trades at $2.83 (market cap $836.71M). The key difference: NICE Ltd is far larger — about 8.1× Sana Biotechnology Inc's market cap, and NICE Ltd is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NICE Ltd for 15 Days and Sana Biotechnology Inc for 23 Days on average.
| NICE | SANA | |
|---|---|---|
Market Cap | $6.81B | $836.71M |
Volume | 382,395 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $137.68 | $5.92 |
52-Week Low | $83.15 | $2.68 |
Typical Hold Time | 15 Days | 23 Days |
Enterprise Value | $6.54B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE Ltd. (NICE) trades at $116.42, up 0.95% on the day, with a bullish technical signal from moving averages. The company shows solid fundamentals with a P/E of 17.08 and strong profitability margins, including a 65.12% gross margin. Recent earnings have consistently beaten expectations, and analyst consensus is bullish with a $124.20 price target. Business developments include being named a leader in IDC MarketScape for contact center platforms, highlighting its competitive position in AI-driven customer experience solutions.
The outlook for NICE is positive, supported by AI-driven growth and a reasonable valuation. Investment opportunities include continued cloud and AI revenue expansion, while risks involve margin compression from heavy investment and market volatility. With no sell ratings from analysts and institutional buying activity, the stock presents a favorable risk-reward profile for growth-oriented investors.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
